[{"id":"9bf88391-bf8e-4bd2-b27f-b745a3c4ca24","acronym":"ECOG-ACRIN E1910","url":"https://clinicaltrials.gov/study/NCT02003222","created_at":"2021-01-18T09:08:51.217Z","updated_at":"2025-02-25T16:36:18.435Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02003222 - ECOG-ACRIN E1910","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1","pipe":"","alterations":" ","tags":["ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 488","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-06"},{"id":"77accf55-b1ad-4e14-aada-f3a5e55d16c9","acronym":"EU PIP Study","url":"https://clinicaltrials.gov/study/NCT05748171","created_at":"2023-02-28T13:01:32.364Z","updated_at":"2024-07-02T16:35:06.949Z","phase":"Phase 2","brief_title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to ","source_id_and_acronym":"NCT05748171 - EU PIP Study","lead_sponsor":"Pfizer","biomarkers":" TP53 • KMT2A • CD22 • TCF3 • PBX1","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD22 positive","tags":["TP53 • KMT2A • CD22 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/17/2023","start_date":" 05/17/2023","primary_txt":" Primary completion: 07/11/2028","primary_completion_date":" 07/11/2028","study_txt":" Completion: 07/09/2031","study_completion_date":" 07/09/2031","last_update_posted":"2024-04-30"},{"id":"08d3cf7e-53db-4d97-bd5c-e37278f8ab16","acronym":"","url":"https://clinicaltrials.gov/study/NCT04787263","created_at":"2021-03-08T12:53:53.051Z","updated_at":"2024-07-02T16:36:32.763Z","phase":"Phase 1/2","brief_title":"CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML","source_id_and_acronym":"NCT04787263","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" TP53 • CD19 • TCF3 • PBX1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • CD19 expression","tags":["TP53 • CD19 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD19-CAR_Lenti T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 03/03/2038","study_completion_date":" 03/03/2038","last_update_posted":"2021-03-26"},{"id":"3e35e0fb-8bd3-48af-8f32-ec9a2649aaaf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00898261","created_at":"2021-01-18T03:26:53.930Z","updated_at":"2024-07-02T16:37:21.923Z","phase":"","brief_title":"Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00898261","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" IL2RA • PBX1 • ISG20","pipe":" | ","alterations":" BCR expression","tags":["IL2RA • PBX1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR expression"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 10/26/2007","start_date":" 10/26/2007","primary_txt":" Primary completion: 07/19/2012","primary_completion_date":" 07/19/2012","study_txt":" Completion: 07/19/2012","study_completion_date":" 07/19/2012","last_update_posted":"2017-05-19"},{"id":"1656111e-821a-41e3-b2bf-fdf36d88d2ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT01505699","created_at":"2021-02-09T13:52:14.518Z","updated_at":"2024-07-02T16:37:22.056Z","phase":"","brief_title":"Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01505699","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" ABL1 • BCR • PBX1","pipe":"","alterations":" ","tags":["ABL1 • BCR • PBX1"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 01/06/2012","start_date":" 01/06/2012","primary_txt":" Primary completion: 02/06/2012","primary_completion_date":" 02/06/2012","study_txt":" Completion: 02/06/2012","study_completion_date":" 02/06/2012","last_update_posted":"2017-05-17"}]